|
Age group, n (%)
|
|
16–25 years
|
2 (2)
|
|
26–35 years
|
7 (8)
|
|
36–45 years
|
7 (8)
|
|
46–55 years
|
17 (20)
|
|
56–65 years
|
23 (28)
|
|
66–75 years
|
21 (25)
|
|
76 years or older
|
6 (7)
|
|
Ethnicity, n (%)
|
|
American Indian or Alaskan Native
|
1 (1)
|
|
Asian
|
4 (5)
|
|
Black or African American
|
2 (2)
|
|
Hispanic
|
4 (5)
|
|
White/Caucasian
|
70 (84)
|
|
Native Hawaiian or other Pacific Islander
|
1 (1)
|
|
Māori
|
1 (1)
|
|
Gout disease duration, n (%)
|
|
Less than 6 months
|
22 (27)
|
|
6 months to 1 year
|
10 (12)
|
|
1–5 years
|
22 (27)
|
|
6–10 years
|
13 (16)
|
|
11–15 years
|
5 (6)
|
|
More than 15 years
|
11 (13)
|
|
Number of gout flares in past 3 months, n (%)
|
|
None
|
16 (19)
|
|
1–2
|
47 (57)
|
|
3 or more
|
20 (24)
|
|
Gout affecting the feet, n (%)
|
77 (93)
|
|
Tophi affecting the feet, n (%)
|
29 (35)
|
|
Location of gout flares in the feet, n (%)
|
|
Big toe joint
|
59 (73)
|
|
Big toe
|
20 (25)
|
|
Lesser toes
|
18 (22)
|
|
Midfoot
|
21 (26)
|
|
Ankle
|
26 (32)
|
|
Heel
|
8 (10)
|
|
Other
|
10 (12)
|
|
Current foot pain, n (%)
|
73 (88)
|
|
Gout medications, n (%)
|
|
Non-steroidal anti-inflammatory drugs
|
27 (33)
|
|
Corticosteroids
|
9 (11)
|
|
Colchicine
|
24 (29)
|
|
Allopurinol
|
34 (41)
|
|
Febuxostat
|
5 (6)
|
|
No medication
|
8 (10)
|
